Marys Medicine

Microsoft word - doa multi-panels rev17 en_no.doc




DIALAB Produktion und Vertrieb von chemisch – technischen Produkten und Laborinstrumenten Gesellschaft m.b.H. A – 2351 Wiener Neudorf, Austria, IZ-NÖ Süd, Hondastrasse, Objekt M55 Phone: ++43 (0) 2236 660910-0, Fax: ++43 (0) 2236 660910-30, e-mail: office@dialab.at "DIAQUICK" Multi-Drug Panels
This test will detect other related compounds, please refer to the Analytical Specificity table in this insert. This assay provides only a preliminary analytical test result. A more specific for human urine samples alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical Multi-3 Drug Panel BZO,COC,MOP
consideration and professional judgment should be applied to any drug of abuse test result, Cont.: 30 panels, individually packed (30x REF Z06576B) particularly when preliminary positive results are obtained. For in vitro diagnostic use only Cont.: 1 panel, individually packed TEST PRINCIPLE
Multi-3/1 Drug Panel BUP, MOP, MTD
Cont.: 30 panels, individually packed (30x REF Z09577B) The "DIAQUICK" Multi-Drug Panels (urine) are immunoassays based on the principle of Cont.: 1 panel, individually packed competitive binding. Drugs which may be present in the urine specimen compete against their respective drug conjugate for binding sites on their specific antibody. During testing, a Multi-4 Drug Panel AMP,COC,MOP,THC
Cont.: 30 panels, individually packed (30x REF Z02575B) urine specimen migrates upward by capillary action. A drug, if present in the urine specimen Cont.: 1 panel, individually packed below its cut-off concentration, will not saturate the binding sites of its specific antibody coated on the particles. The antibody coated particles will then be captured by the immobi- Multi-5 Drug Panel BZO,COC,MET,MOP,THC
lized drug conjugate and a visible colored line will show up in the test line region of the Cont.: 30 panels, individually packed (30x REF Z05236B) specific drug strip. The colored line will not form in the test line region if the drug level is Cont.: 1 panel, individually packed above its cut-off concentration because it will saturate all the binding sites of the antibody Multi-5/3 Drug Panel AMP,COC,MET,MOP,THC
coated on the particles. A drug-positive urine specimen will not generate a colored line in the Cont.: 30 panels, individually packed (30x REF Z06502B) specific test line region of the strip because of drug competition, while a drug-negative urine Cont.: 1 panel, individually packed specimen or a specimen containing a drug concentration less than the cut-off will generate a Multi-5/4 Drug Panel AMP,COC,MDMA,MOP,THC
line in the test line region. To serve as a procedural control, a colored line will always appear Cont.: 30 panels, individually packed (30x REF Z11504B) at the control line region indicating that proper volume of specimen has been added and Cont.: 1 panel, individually packed membrane wicking has occurred. Multi-5/6 Drug Panel AMP,BZO,COC,MOP,THC
WARNINGS AND PRECAUTIONS
Cont.: 30 panels, individually packed (30x REF Z06506B) For medical and other in vitro diagnostic use only. Do not use after the expiration date. Cont.: 1 panel, individually packed The test panel should remain in the sealed pouch until use. Multi-6 Drug Panel BZO,COC,MET,MOP,MTD,THC
All specimens should be considered potential y hazardous and handled in the same Cont.: 30 panels, individually packed (30x REF Z98907B) manner as an infectious agent. Cont.: 1 panel, individually packed The used test panels should be discarded according to federal, state and local regula- Multi-6/1 Drug Panel AMP,BZO,COC,MET,MOP,THC
Cont.: 30 panels, individually packed (30x REF Z03220B) REAGENTS
Cont.: 1 panel, individually packed Each test line contains anti-drug mouse monoclonal antibody and corresponding drug- Multi-6/3 Drug Panel BUP, BZO, COC, MTD, OPI, THC
protein conjugates. The control line contains goat anti-rabbit IgG polyclonal antibodies and Cont.: 30 panels, individually packed (30x REF Z08930B) Cont.: 1 panel, individually packed Multi-6/4 Drug Panel AMP,BUP,BZO,MET,MOP,THC
Cont.: 30 panels, individually packed (30x REF Z08940B) The "DIAQUICK" Multi-Drug Panels can be stored refrigerated or at room temperature (2- Cont.: 1 panel, individually packed 30°C). The test panel is stable through the expiration date printed on the sealed pouch. The test panel must remain in the sealed pouch until use. DO NOT FREEZE. Do not use beyond Multi-6/6 Drug Panel BUP,COC,MET,MOP,MTD,THC
the expiration date. Cont.: 30 panels, individually packed (30x REF Z13960B) Cont.: 1 panel, individually packed SAMPLE COLLECTION AND PREPARATION
Multi-6/7 Drug Panel BUP,BZO,COC,MOP,MTD,THC
The urine must be collected in a clean and dry container. Urine collected at any time of the Cont.: 30 panels, individually packed (30x REF Z09970B) day may be used. Urine specimens exhibiting visible precipitations should be centrifuged, Cont.: 1 panel, individually packed filtered or allowed to settle to obtain a clear specimen for testing. Urine specimens may be stored at 2-8°C for up to 48 h prior to testing. For prolonged storage, specimens may be Multi-6/10 Drug Panel AMP,BZO,COC,MOP,MTD,THC
Cont.: 30 panels, individually packed (30x REF Z11911B) frozen and stored below –20°C. Frozen specimens should be thawed and mixed before Cont.: 1 panel, individually packed Multi-7 Drug Panel AMP,BUP,BZO,COC,MTD,MOP,THC
ASSAY PROCEDURE
Cont.: 30 panels, individually packed (30x REF Z12730B) Allow the test panel, urine specimen, and/or controls to equilibrate to room tempera-
Cont.: 1 panel, individually packed ture (15-30°C) prior to testing
Multi-10 Drug Panel AMP,BAR,BZO,COC,MDMA,MET,MOP,MTD,TCA,THC
Remove the test panel from the sealed pouch and use it as soon as possible. Cont.: 30 panels, individually packed (30x REF Z04230B) Take off the protective cap plugged Cont.: 10 panels, individually packed (10x REF Z04230B) on the test panel. With arrows Cont.: 1 panel, individually packed pointing towards the urine Multi-10/1 Drug Panel AMP,BAR,BZO,BUP,COC,MDMA,MET,MOP,MTD,THC
specimen, immerse the test panel Cont.: 30 panels, individually packed (30x REF Z05235B) vertically into the urine specimen Cont.: 10 panels, individually packed (10x REF Z05235B) for 10-15 seconds. Do not allow Cont.: 1 panel, individually packed the urine sample to touch the plastic cassette when immersing Multi-10/2 Drug Panel AMP,BAR,BZO,COC,MDMA,MOP,MTD,OPI,TCA,THC
Cont.: 30 panels, individually packed (30x REF Z06102B) the test device into the urine Cont.: 1 panel, individually packed sample. Avoid immersion of the cassette deeper than the mark Multi-10/3 Drug Panel AMP, BZO,COC,MDMA,MOP,MTD,OPI,PCP,TCA,THC
indicated with the arrows on the Cont.: 30 panels, individually packed (30x REF Z06103B) device and avoid any direct contact Cont.: 1 panel, individually packed of the sample with the test region. Multi-10/4 Drug Panel AMP,BAR,BUP,BZO,COC,MDMA,MET,MTD,OPI,THC
3. Put the protective cap back onto Cont.: 30 panels, individually packed (30x REF Z06104B) the test panel. Place the test panel Cont.: 1 panel, individually packed on a non-absorbent flat surface, start the timer and wait for the red line(s) to appear. Multi-10/5 Drug Panel AMP,BAR,BZO,BUP,COC,MET,MOP,MTD,TCA,THC
Read the results at 5 minutes. Do not interpret results after 10 minutes. Cont.: 30 panels, individually packed (30x REF Z06105B) Cont.: 1 panel, individually packed INTERPRETATION OF RESULTS
Multi-10/6 Drug Panel AMP,BAR,BZO,COC,MET,MOP,MTD,PCP,TCA,THC
NEGATIVE: A colored line in the control region (C) and a colored line in the test line
Cont.: 30 panels, individually packed (30x REF Z06106B) region (T) for a specific drug indicate a negative results. This indicates that the drug
Cont.: 1 panel, individually packed concentration in the urine specimen is below the designated cut-off level for that specific drug. Multi-10/7 Drug Panel AMP,BAR,BZO,COC,MET,MTD,OPI,PCP,TCA,THC
Cont.: 30 panels, individually packed (30x REF Z06107B) *NOTE: The shade of color in the test region (T) may vary, but it should be considered Cont.: 1 panel, individually packed negative whenever there is even a faint pink line. All products contain a package insert!
POSITIVE: A colored line in the control line region (C) but no line in the test line region
(T) for a specific drug indicates a positive results.
This indicates that the drug concentra-
For in vitro diagnostic use only. For use by medical professionals only.
tion in the urine specimen exceeds the designated cut-off level. For diagnosis and therapeutic monitoring only.
INVALID: Control line fails to appear. Insufficient specimen volume or incorrect procedural
INTENDED USE
techniques are the most likely reasons for control line failure. Review the procedure and The "DIAQUICK" Multi-Drug Panels (urine) are rapid, lateral flow chromatographic immunoas- repeat the test using a new test panel. If the problem persists, discontinue using the lot says for the simultaneous, qualitative detection of the fol owing drugs and their metabolites: immediately and contact your local distributor Parameter
Short Calibrator Substance
QUALITY CONTROL
Amphetamine
AMP d-Amphetamine A procedural control is included in the test. A red line appearing in the control region (C) is BAR Secobarbital considered an internal procedural control. It confirms sufficient specimen volume, adequate BUP Buprenorphine membrane wicking and correct procedural technique. Control standards are not supplied with this kit; however, it is recommended that positive and negative controls be tested as good laboratory practice to confirm the test procedure and to verify proper test performance. COC Benzoylecgonine LIMITATIONS
MDMA d,l Methylenedioxymethamphetamine 1. The "DIAQUICK" Multi-Drug Panels (urine) provide only a preliminary analytical result. MET d-Methamphetamine A more specific chemical method must be used to obtain a confirmed result. Gas chro- Methadone
matography/mass spectrometry (GC/MS) is the preferred confirmatory method. Opiate, Morphine, Heroine
2. It is possible that technical or procedural errors, as wel as other interfering substances in the urine specimen may cause erroneous results. Opiate, Morphine, Heroine
3. Adulterants, such as bleaching agents in urine specimens may produce erroneous PCP Phencyclidine results regardless of the analytical method used. If adulteration is suspected, the test Tricyclic Antidepressants
TCA Nortriptyline should be repeated with another urine specimen. THC 11-nor-∆9-THC-9-COOH 50 A positive result indicates presence of the drug or its metabolites but does not indicate Mag. Simone Sturm-E.


DIALAB Produktion und Vertrieb von chemisch – technischen Produkten und Laborinstrumenten Gesellschaft m.b.H. A – 2351 Wiener Neudorf, Austria, IZ-NÖ Süd, Hondastrasse, Objekt M55 Phone: ++43 (0) 2236 660910-0, Fax: ++43 (0) 2236 660910-30, e-mail: office@dialab.at the level of intoxication, administration route or concentration in urine. ANALYTICAL SPECIFICITY
5. A negative result may not necessarily indicate drug-free urine. Negative results can be The fol owing tables lists the concentration of compounds (ng/mL) that are detected positive obtained if a drug is present but below the cut-off level of the test. in urine by the "DIAQUICK" Multi-Drug Panels (urine) at 5 minutes. 6. The "DIAQUICK" Multi-Drug Panels (urine) do not distinguish between drugs of abuse AMPHETAMINES (AMP)
AMP ECSTASY
and certain medications. d,l-Amphetamine sulfate 200 (±) 3,4-Methylenedioxymethamphetamine HCl 7. A positive result might be obtained from certain foods or food supplements. l-Amphetamine 25,000 (±) 3,4-Methylenedioxyamphetamine HCl (MDA) PERFORMANCE CHARACTERISTICS
d-Amphetamine 1,000 3,4-Methylenedioxyethylamphetamine (MDE) (±) 3,4-Methylenedioxyamphetamine 400 OPIATE, MORPHINE, HEROINE
ACCURACY
Maprotiline 50,000 A side-by-side comparison was conducted using the "DIAQUICK" Multi-Drug Panels (urine) Methoxyphenamine 6,000 and commercial y available drug rapid tests. Testing was performed on approximately 250 specimens. Presumptive positive results were confirmed by GC/MS. The fol owing results BAR Hydromorphone
% Agreement with Commercial Kit
3,000 6-Monoacethylmorphine Positive Agreement
Negative Agreement
Total Results
300 Morphine 3-β-d-glucuronide 800 6,000 Norcodeine Cyclopentobarbital 5,5-Diphenylhydantoin 6,000 MARIHUANA/CANNABIS
300 11-nor-∆8- THC-9 COOH 11-nor-∆9- THC-9 COOH BZO ∆8- THC
a-hydroxyalprazolam 1,500 OPIATE, MORPHINE, HEROINE
* NOTE: Based on GC/MS instead of Commerical Kit. % Agreement with GC/MS
Chlordiazepoxide 780 Ethylmorphine Positive Agreement
Negative Agreement
Total Results
390 Hydromorphone Clorazepate dipotassium 780 6-Monoacethylmorphine Desalkylflurazepam 200 Morphine 3-β-d-glucuronide 2,000 6,250 Norcodeine RS-Lorazepam glucuronide Norchlordiazepoxide 100 PHENCYCLIDINE
780 Phencyclidine 300 4-Hydroxyphencyclidine ANALYTICAL SENSITIVITY
100 TRICYCLIC ANTIDEPRESSANTS
A drug-free urine pool was spiked with drugs to the concentrations at ± 50% cut-off and ± 3,100 Amitriptyline 25% cut-off. The results are summarized below: BUP Clomipramine 50,000
Cyclobenzaprine AMP
BAR BUP BZO COC
Drug Conc.
n
Buprenorphine 3-d-Glucuronide Norbuprenorphine -50% Cut-off
3-d-Glucuronide 100 -25% Cut-off
COC Maprotiline 1,500
Benzoylecgonine 300 +25% Cut-off
200 Nortriptyline +50% Cut-off
Cocaethylene 12,500 30,000 Promazine MTD
MET
MDMA MOP
OPI
METHADONE
MTD Promethazine 25,000
Drug Conc.
Doxylamine 100,000 -50% Cut-off
-25% Cut-off
d-Methamphetamine +25% Cut-off
l-Methamphetamine 12,500 +50% Cut-off
Mephentermine 50,000 PCP
TCA
THC
Drug Conc.
REFERENCES
-50% Cut-off
Hawks RL, CN Chiang. Urine Testing for Drugs of Abuse. National Institute for Drug Abuse -25% Cut-off
(NIDA), Research Monograph 73, 1986. Tietz NW. Textbook of Clinical Chemistry. W.B. Saunders Company. 1986; 1735. +25% Cut-off
Stewart DJ, Inaba T, Lucassen M, Kalow W. Clin. Pharmacol. Ther. April 1979; 25 ed: 464, +50% Cut-off
Ambre J. J. Anal. Toxicol.1985; 9:241. Winger, Gail, A Handbook of Drug and Alcohol Abuse, Third Edition, Oxford Press, 1992, A study was conducted to determine the cross-reactivity of the test with compounds in either Robert DeCresce. Drug Testing in the workplace, 1989 page 114. drug-free urine or drug positive urine. The fol owing compounds did not show a cross- Glass, IB. The International Handbook of Addiction Behavior. Routledge Publishing, New reactivity when tested with the "DIAQUICK" Multi-Drug Panels (urine) at a concentration of York, NY. 1991; 216 B. Cody, J.T., "Specimen Adulteration in drug urinalysis. Forensic Sci. Rev., 1990, 2:63. Non Cross-Reacting Compounds:
C. Tsai, S.C. et.al., J. Anal. Toxicol. 1998; 22 (6): 474 Acetophenetidin Cortisone d-Pseudoephedrine 10. Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 6th Ed. Biomedical Publ., N-Acetylprocainamide Creatinine Foster City, CA 2002. Acetylsalicylic acid Deoxycorticosterone 11. Hardman JG, Limbird LE. Goodman and Gilman's: The Pharmacological Basis for Thera- Aminopyrine Dextromethorphan Loperamide Salicylic peutics. 10th Edition. McGraw Hill Medical Publishing, 2001; 208-209. Amoxicillin Diclofenac Meprobamate Ampicillin Diflunisal Methoxyphenamine Apomorphine Diphenhydramine acid Tetracycline Aspartame Ethyl-p-aminobenzoate Naproxen Tetrahydrocortisone, β-Estradiol Niacinamide Estrone-3-sulfate Tetrahydrocortisone Tetrahydrozoline Bilirubin Fenoprofen d,l-Brompheniramine Furosemide Caffeine Gentisicacid Cannabidiol Hemoglobin Oxolinic acid Tolbutamide Chloralhydrate Hydralazine Oxymetazoline Triamterene Chloramphenicol Hydrochlorothiazide Papaverine Chlorothiazide Hydrocortisone Penicillin-G d,l-Chlorpheniramine o-Hydroxyhippuric acid Perphenazine Chlorpromazine 3-Hydroxytyramine Cholesterol d,l-Isoproterenol Prednisone Verapamil Clonidine Isoxsuprine Mag. Simone Sturm-E.




DIALAB Produktion und Vertrieb von chemisch – technischen Produkten und Laborinstrumenten Gesellschaft m.b.H. A – 2351 Wiener Neudorf, Austria, IZ-NÖ Süd, Hondastrasse, Objekt M55 Phone: ++43 (0) 2236 660910-0, Fax: ++43 (0) 2236 660910-30, e-mail: office@dialab.at "DIAQUICK" Multi-Drug Paneler
Denne testen vil oppdage andre beslektede forbindelser, vennligst se tabellen Analytisk spesifisitet i dette pakningsvedlegget. Denne analysen gir kun et foreløpig analytisk resultat. for humane urinprøver En mer spesifikk alternativ kjemisk fremgangsmåte må brukes for å få et bekreftet analytisk resultat. Gasskromatografi/massespektrometri (GC/MS) er den foretrukne bekreftende Multi-3 Drug Panel BZO,COC,MOP
metode. Klinisk vurdering og profesjonelt skjønn skal anvendes for alle testresultater relatert Innhold: 30 Paneler, individuelt pakket (30x REF Z06576B) til misbruksanalyser, særlig når de foreløpige resultatene er positive. Kun til in vitro diagnos- Innhold: 1 Panel, individuelt pakket Multi-3/1 Drug Panel
Innhold: 30 Paneler, individuelt pakket (30x REF Z09577B) TEST PRINSIPP
Innhold: 1 Panel, individuelt pakket "DIAQUICK" Multi-Drug Panels (urin) er immunanalyser basert på prinsippet om konkurrer-ende binding. Narkotika som kan være tilstede i urinprøven konkurrerer mot deres respektive Multi-4 Drug Panel AMP,COC,MOP,THC
Innhold: 30 Paneler, individuelt pakket (30x REF Z02575B) narkotiske konjugat for bindingssteder på deres spesifikke antistoff. Under testing, vandrer Innhold: 1 Panel, individuelt pakket urinprøven oppover med kapillæreffekt. Narkotika, hvis tilstede i urinprøven under cut-off konsentrasjon, vil det ikke mette bindingsstedene for sitt spesifikke antistoff belag på Multi-5 Drug Panel BZO,COC,MET,MOP,THC
partiklene. Antistoffbelagte partikler vil da bli fanget opp av det immobiliserte stoffkonjugatet Innhold: 30 Paneler, individuelt pakket (30x REF Z05236B) og en synlig farget linje vil dukke opp i testlinjeområdet på teststrimmelen for det spesifikke Innhold: 1 Panel, individuelt pakket stoffet. Det dannes ingen farget linje i testlinjeområdet hvis stoffnivået er over cut-off Multi-5/3 Drug Panel AMP,COC,MET,MOP,THC
konsentrasjonen, fordi de metter alle bindingsstedene til antistoffet belagt på partiklene. En Innhold: 30 Paneler, individuelt pakket (30x REF Z06502B) urinprøve som tester positivt for narkotika, vil ikke generere en farget linje i det spesifikke Innhold: 1 Panel, individuelt pakket testlinjeområdet på teststrimmelen på grunn av konkurrerende stoffer, men en urinprøve som Multi-5/4 Drug Panel AMP,COC,MDMA,MOP,THC
tester negativt for narkotika eller en prøve som inneholder en stoffkonsentrasjon som er Innhold: 30 Paneler, individuelt pakket (30x REF Z11504B) lavere enn cut-off verdien, vil generere en linje i testlinjeområdet. For å fungere som en Innhold: 1 Panel, individuelt pakket prosedyrekontroll, vil det alltid vises en farget linje i kontrollinjeområdet, som indikerer at riktig prøvevolum er tilsatt og at fukttranssport på membranen har foregått. Multi-5/6 Drug Panel AMP,BZO,COC,MOP,THC
Innhold: 30 Paneler, individuelt pakket (30x REF Z06506B) ADVARSLER OG FORHOLDSREGLER
Innhold: 1 Panel, individuelt pakket Kun for medisinsk og annen in vitro diagnostisk bruk. Ikke bruk etter utløpsdatoen. Multi-6 Drug Panel BZO,COC,MET,MOP,MTD,THC
Testpanelet må oppbevares i den forseglede posen til det skal brukes. Innhold: 30 Paneler, individuelt pakket (30x REF Z98907B) Alle prøver skal betraktes som potensielt farlige og håndteres på samme måte som Innhold: 1 Panel, individuelt pakket smittefarlige materialer. Multi-6/1 Drug Panel AMP,BZO,COC,MET,MOP,THC
Brukte testpaneler skal kasseres i henhold til statlige og lokale forskrifter Innhold: 30 Paneler, individuelt pakket (30x REF Z03220B) REAGENSER
Innhold: 1 Panel, individuelt pakket Hver testlinje inneholder anti-narkotika monoklonalt antistoff fra mus og tilhørende protein- Multi-6/3 Drug Panel
BUP, BZO, COC, MTD, OPI, THC konjugater fra denne narkotikaen. Kontrollinjen inneholder geit anti-kanin-IgG polyklonale Innhold: 30 Paneler, individuelt pakket (30x REF Z08930B) antistoffer og kanin IgG. Innhold: 1 Panel, individuelt pakket OPPBEVARING
Multi-6/4 Drug Panel AMP,BUP,BZO,MET,MOP,THC
Innhold: 30 Paneler, individuelt pakket (30x REF Z08940B) "DIAQUICK" Multi-Drug Panelene kan oppbevares i kjøleskap eller ved romtemperatur (2-30 Innhold: 1 Panel, individuelt pakket °C). Testpanelet er stabilt til og med utløpsdatoen som er trykt på den forseglede posen. Testpanelet må oppbevares i den forseglede posen til det skal brukes. MÅ IKKE FRYSES. Multi-6/6 Drug Panel BUP,COC,MET,MOP,MTD,THC
Ikke bruk etter utløpsdatoen. Innhold: 30 Paneler, individuelt pakket (30x REF Z13960B) Innhold: 1 Panel, individuelt pakket PRØVETAKING OG KLARGJØRING
Multi-6/7 Drug Panel BUP,BZO,COC,MOP,MTD,THC
Urinprøven må innhentes i en ren og tørr beholder. Urin samlet inn når som helst på dagen Innhold: 30 Paneler, individuelt pakket (30x REF Z09970B) kan anvendes. Urinprøver med synlig utfelling bør sentrifugeres, filtreres eller få bunnfalle Innhold: 1 Panel, individuelt pakket seg for å få klar prøve for testing. Urinprøver kan lagres ved 2-8°C i opptil 48 timer før analysering. For langvarig lagring, kan prøvene fryses og lagres under -20 °C. Frosne prøver Multi-6/10 Drug Panel AMP,BZO,COC,MOP,MTD,THC
Innhold: 30 Paneler, individuelt pakket (30x REF Z11911B) må tines og blandes før testing. Innhold: 1 Panel, individuelt pakket Multi-7 Drug Panel AMP,BUP,BZO,COC,MTD,MOP,THC
La testpanelet, urinprøven, og/eller kontrollene oppnå romtemperatur (15-30 °C) før
Innhold: 30 Paneler, individuelt pakket (30x REF Z12730B) testing.
Innhold: 1 Panel, individuelt pakket Ta testpanelet ut av den forseglede posen og bruk det så snart som mulig. Multi-10 Drug Panel AMP,BAR,BZO,COC,MDMA,MET,MOP,MTD,TCA,THC
2. Ta av beskyttelseshetten som er Innhold: 30 Paneler, individuelt pakket (30x REF Z04230B) plugget på testpanelet. Med pilene Innhold: 10 Paneler, individuelt pakket (10x REF Z04230B) pekende mot urinprøven, dypp Innhold: 1 Panel, individuelt pakket testpanelet vertikalt i urinprøven for Multi-10/1 Drug Panel AMP,BAR,BZO,BUP,COC,MDMA,MET,MOP,MTD,THC
10-15 sekunder. Ikke la urinprøven Innhold: 30 Paneler, individuelt pakket (30x REF Z05235B) komme i kontakt med plastkassetten Innhold: 10 Paneler, individuelt pakket (10x REF Z05235B) mens testenheten dyppes i Innhold: 1 panel, individually packed urinprøven. Unngå nedsenkning av kassetten dypere enn merket med Multi-10/2 Drug Panel AMP,BAR,BZO,COC,MDMA,MOP,MTD,OPI,TCA,THC
Innhold: 30 Paneler, individuelt pakket (30x REF Z06102B) pilene på enheten, og unngå at Innhold: 1 Panel, individuelt pakket testområdet kommer direkte i kontakt med prøven. Multi-10/3 Drug Panel AMP,
Innhold: 30 Paneler, individuelt pakket (30x REF Z06103B) 3. Sett beskyttelseshetten tilbake på Innhold: 1 Panel, individuelt pakket testpanelet. Plasser testpanelet på et ikke-absorberende flatt underlag, Multi-10/4 Drug Panel AMP,BAR,BUP,BZO,COC,MDMA,MET,MTD,OPI,THC
start tidtakeren og vent på at den Innhold: 30 Paneler, individuelt pakket (30x REF Z06104B) (de) røde linjen(e) skal vises. Avles Innhold: 1 Panel, individuelt pakket resultatene etter 5 minutter. Ikke tolk resultater etter 10 minutter. Multi-10/5 Drug Panel AMP,BAR,BZO,BUP,COC,MET,MOP,MTD,TCA,THC
Innhold: 30 panels, individually packed (30x REF Z06105B) TOLKNING AV RESULTATER
Innhold: 1 Panel, individuelt pakket NEGATIV: En farget linje i kontrollinjeområdet (C) og en farget linje i testlinjeområdet
Multi-10/6 Drug Panel AMP,BAR,BZO,COC,MET,MOP,MTD,PCP,TCA,THC
(T) for et bestemt narkotisk stoff indikerer et negativt resultat. Dette indikerer at
Innhold: 30 Paneler, individuelt pakket (30x REF Z06106B) konsentrasjonen for narkotiske stoffet i urinprøven er under angitt cut- off nivå for dette Innhold: 1 Panel, individuelt pakket bestemte narkotika. Multi-10/7 Drug Panel AMP,BAR,BZO,COC,MET,MTD,OPI,PCP,TCA,THC
*MERK: Fargenyansen i testlinjeområdet (T) kan variere, men resultatet skal anses som Innhold: 30 Paneler, individuelt pakket (30x REF Z06107B) negativet selv om det bare vises en svak rosa linje. Innhold: 1 Panel, individuelt pakket POSITIV: En farget linje i kontrollinjeområdet (C), men ingen linje i testlinjeområdet (T)
Alle produktene inneholder et pakningsvedlegg!
for et bestemt narkotika indikerer et positivt resultat. Dette indikerer at konsentrasjonen
Kun til in vitro diagnostisk bruk. Skal kun brukes av medisinsk fagpersonell. Kun til
av narkotikaen i urinprøven overstiger det angitte cut-off nivået. diagnostikk og terapeutisk overvåkning.
UGYLDIG: Kontrollinjen vises ikke. Utilstrekkelig prøvevolum eller feil prosedyreteknikk er
TILTENKT BRUK
de mest sannsynlige årsakene til manglende kontrollinje. Gå gjennom prosedyren og gjenta "DIAQUICK" Multi-Drug Paneler (urin) er raske, lateral flytkromatografiske immunanalyser for testen med et nytt testpanel. Hvis problemet vedvarer, slutt å bruke loten umiddelbart og samtidig, kvalitativ påvisning av følgende narkotiske stoffer og deres metabolitter: kontakt din lokale leverandør. Parameter
Kort Kalibrator
Amfetamin
AMP d-Amphetamin En intern prosedyrekontroll er inkludert i testen. Den røde linjen som vises i kontrollinjeo-mrådet (C), er en intern prosedyrekontrol . Det bekrefter tilstrekkelig prøvevolum, tilstrekkelig BAR Secobarbital fukttransportering på membranen og riktig prosedyreteknikk. Kontrol er følger ikke med dette Buprenorfin
kitet. Det anbefales imidlertid at positive og negative kontrol er testes for god laboratori- epraksis, for å bekrefte testprosedyren og til å verifisere riktig testytelse. COC Benzoylecgonin MDMA d,l Metylenedioxymetamfetamin 1. "DIAQUICK" Multi-Drug Paneler (urin) gir kun et foreløpig analytisk resultat. En mer MET d-Metamfetamin spesifikk kjemisk metode må brukes for å få bekreftet resultatet. Gasskromatogra- fi/massespektrometri (GC/GS) en den foretrukne bekreftende metode. 2. Det er mulig at tekniske eller prosedyrefeil, samt andre forstyrrende stoffer i urinprøven Opiat, Morfin, Heroin
kan gi feilaktige resultater. Opiat, Morfin, Heroin
3. Forfalskningsmidler, slik som blekemiddel i urinprøver, kan gi feilaktige resultater uavhen- Fensyklidin
gig av den analytiske metoden som brukes. Hvis forfalskning mistenkes, bør testen gjen-tas med en annen urinprøve. Trisykliske antidepressiva
TCA Nortriptylin 4. Et positivt resultat indikerer tilstedeværelse av det narkotiske stoffet eller dets metabolitter, Marihuana/Cannabis
THC 11-nor-∆9-THC-9-COOH 50 men angir ikke nivået på rus, administrasjonsvei eller konsentrasjon i urin. Mag. Simone Sturm-E.


DIALAB Produktion und Vertrieb von chemisch – technischen Produkten und Laborinstrumenten Gesellschaft m.b.H. A – 2351 Wiener Neudorf, Austria, IZ-NÖ Süd, Hondastrasse, Objekt M55 Phone: ++43 (0) 2236 660910-0, Fax: ++43 (0) 2236 660910-30, e-mail: office@dialab.at 5. Et negativt resultat indikerer nødvendigvis at urinen ikke inneholder narkotika. Negative resultater kan oppnås dersom narkotika er tilstede, men under cut-off nivået av testen. (±) 3,4-Metylendioxymetamfetamin HCl 6. "DIAQUICK" Multi-Drug Panels (urin) skiller ikke mellom narkotika misbruk og enkelte 25 000 (±) 3,4-Metylendioxyamfetamin HCl (±) 3,4-Metylendioxyetylmetamftamin 7. Et positivt resultat kan oppnås fra visse matvarer eller kosttilskudd. OPIAT, MORFIN, HEROIN
50 000 Kodein 200 YTELSE OG EGENSKAPER
Hydrokodon 50 000 En side-ved-side-sammenligning ble gjennomført ved hjelp av "DIAQUICK" Multi-Drug Paneler Hydromorfon 3 000 (urin) og kommersielt tilgjengelige hurtigtester for påvisning av narkotika. Testene ble utført på 250 prøver. Presumptive positive resultater ble bekreftet ved GC/MS. Følgende resultater ble 6-Monacetylmorfin 400 Morfin 3-β-d-glukuronid % samsvar med kommersielt kit
Positivt samsvar
Negativt samsvar
Totalt samsvar
Oksymorfon 50 000 25 000 Prokain 15 000 Cannabinol 20 000 11-nor-∆8- THC-9 COOH 11-nor-∆9- THC-9 COOH a-hydroxyalprazolam 1 500 OPIAT, MORFIN, HEROIN
Hydrokodon 50 000 * MERK: Basert på GC/MS i stedet for kommersielt kit. Hydromorfon 12 500 % Übereinstimmung mit GC/MS
Levorfanol 25 000 6-Monacetylmorfin 3 000 Positivt samsvar
Negativt samsvar
Totalt samsvar
Morfin 3-β-d-glukuronid Oksymorfon 25 000 Norklordiazepoksid 100 FENSYKLIDIN (PCP)
4-Hydroxyfensyklidin 6 250 TRISYKLISKE ANTIDEPRESSIVA
Amitriptylin 1 500 Klomipramin 50 000 Sykobenzaprin 1 500 ANALYTISK SENSITIVITET
En urinpool fri for narkotika ble tilsatt narkotikum med cut off verdier på ± 50% og ± 25% . Resultatene oppsummeres nedenfor: Matprotilin 1 500 AMP
BAR BUP BZO COC
n
Nortriptylin 1 000 12 500 Perfenazin 25 000 30 000 Promazin 3 000 Prometazin 25 000 Trimipramin 3 000 MTD
MET
MDMA MOP
OPI
(±) 3,4-Metylendioxymetamfetamin REFERANSER
Hawks RL, CN Chiang. Urine Testing for Drugs of Abuse. National Institute for Drug Abuse PCP
TCA
THC
(NIDA), Research Monograph 73, 1986. Tietz NW. Textbook of Clinical Chemistry. W.B. Saunders Company. 1986; 1735. Stewart DJ, Inaba T, Lucassen M, Kalow W. Clin. Pharmacol. Ther. April 1979; 25 ed: 464, Ambre J. J. Anal. Toxicol.1985; 9:241. Winger, Gail, A Handbook of Drug and Alcohol Abuse, Third Edition, Oxford Press, 1992, Robert DeCresce. Drug Testing in the workplace, 1989 page 114. Det ble gjennomført en studie for å bestemme testens kryssreaktivitet med forbindelse i Glass, IB. The International Handbook of Addiction Behavior. Routledge Publishing, New enten narkotikafri urin eller narkotikapositiv urin. Følgende forbindelser viste ingen kryssre- York, NY. 1991; 216 aktivitet når testet med "DIAQUICK" Multi-Drug Paneler (urin) i en konsentrasjon på 100 B. Cody, J.T., "Specimen Adulteration in drug urinalysis. Forensic Sci. Rev., 1990, 2:63. C. Tsai, S.C. et.al., J. Anal. Toxicol. 1998; 22 (6): 474 10. Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 6th Ed. Biomedical Publ., Forbindelser uten kryssreaktivitet:
Foster City, CA 2002. Acetophenetidin Cortison d-Pseudoephedrin 11. Hardman JG, Limbird LE. Goodman and Gilman's: The Pharmacological Basis for Thera- N-Acetylprocainamid Creatinin peutics. 10th Edition. McGraw Hill Medical Publishing, 2001; 208-209. Acetylsalicylsäure Deoxycorticosteron Aminopyrin Dextromethorphan Loperamid Salicylsäure Amoxicillin Diclofenac Meprobamat Ampicillin Diflunisal Methoxyphenamin l-Ascorbinsäure Digoxin Methylphenidat Sulindac Apomorphin Diphenhydramin Aspartam Ethyl-p-aminobenzoat Naproxen Tetrahydrocortison β-Estradiol Niacinamid 3-acetat Benzilinäsure Estron-3-sulfat Nifedipin Tetrahydrocortison Benzoesäure Erythromycin Norethindron Tetrahydrozolin Bilirubin Fenoprofen d,l-Brompheniramin Furosemid Koffein Gentisinsäure Cannabidiol Hämoglobin Oxolinsäure Tolbutamid Chloralhydrat Hydralazin Oxymetazolin Triamteren Chloramphenicol Hydrochlorothiazid Chlorothiazid Hydrocortison Penicillin-G Trimethoprim d,l-Chlorpheniramin o-Hydroxyhippursäure Chlorpromazin 3-Hydroxytyramin Cholesterol d,l-Isoproterenol Prednison Verapamil Clonidin Isoxsuprin ANALYTISK SPESIFISITET
Tabellene nedenfor viser konsentrasjonen av stoffer (ng/mL) som blir funnet positive i urin av
"DIAQUICK" Multi-Drug Panels (urin) på 5 minutter.
Mag. Simone Sturm-E.

Source: http://www.medic24.no/wp-content/uploads/2014/12/DOA-Multi-Panels-Rev17-en_no.pdf

3mpl.univ-angers.fr

Effect of Particle Morphology and Interaction on the Stabilization of Water/Water Emulsions by Protein Particles Alberto GONZALEZ-JORDAN, Taco NICOLAI, Lazhar BENYAHIA alberto.gonzalez_jordan.etu@univ-lemans.fr Université du Maine, IMMM UMR CNRS 6283, PCI, 72085 Le Mans Cedex Category : ฀ Molécules ฀ Matériaux Water/water (W/W) emulsions have a promising potential for many applications, especially in the food and cosmetics industries. These emulsions cannot be stabilized by surfactants, but in recent years it was found that they can be stabilized by adding solid particles in a manner similar to so-called Pickering oil/water emulsions. Protein particles in the form of microgels, fractal aggregates or fibrils were made from the same protein, ß-lactoglobulin by heating at different conditions. The effect of the morphology on the stability and structure of W/W emulsions made by mixing aqueous solutions of PEO and dextran was investigated at different pH. Interestingly, excess proteins partioned to the dextran phase at pH>4 and to the PEO at pH<3.0. Fibrils were found to be most effective stabilizers at pH 7, whereas fractals were most effective at pH 3. At pH values between 5.5 and 3.5 the protein particles aggregated leading to cold gelation. If excess proteins were in the continuous phase W/W emulsion formed gels that were very weak, but strong enough to prevent creaming of sedimentation of the dispersed droplets. If excess proteins were in the dispersed phase, the droplets were transformed into stable microscopic protein particles.

Op-jeen150272 1.8

Journal of Economic Entomology Advance Access published September 5, 2015 Spray Toxicity and Risk Potential of 42 Commonly Used Formulations of Row Crop Pesticides to Adult Honey Bees (Hymenoptera: Apidae) YU CHENG ZHU,1,2 JOHN ADAMCZYK,3 THOMAS RINDERER,4 JIANXIU YAO,1 ROBERT DANKA,4 RANDALL LUTTRELL,1 AND JEFF GORE5 J. Econ. Entomol. 1–8 (2015); DOI: 10.1093/jee/tov269